LQDA
Liquidia Corporation
Price Chart
Latest Quote
$75.54
+1.50 (+2.03%)
Current Price
| Previous Close | $74.04 |
| Open | $73.82 |
| Day High | $76.35 |
| Day Low | $72.22 |
| Volume | 1,904,194 |
Stock Information
| Shares Outstanding | 88.93M |
| Total Debt | $184.82M |
| Cash Equivalents | $222.79M |
| Revenue | $288.06M |
| Net Income | $22.30M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $6.72B |
| P/E Ratio | 444.35 |
| EPS (TTM) | $0.17 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.68B |
| Sales | $288.06M |
| Income | $22.30M |
| Book/sh | $1.23 |
| Cash/sh | $2.51 |
| Employees | 216 |
Financial Ratios
| Quick Ratio | 1.98 |
| Current Ratio | 2.22 |
| Debt/Eq | 170.22 |
Returns & Margins
| ROA | 9.05% |
| ROE | 28.18% |
| Gross Margin | 91.81% |
| Operating Margin | 46.29% |
| Profit Margin | 7.74% |
Ownership
| Insider Ownership | 12.72% |
| Institutional Ownership | 70.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.56 |
| P/S | 23.32 |
| P/B | 61.41 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $72.38 |
Technical Indicators
| SMA20 | $66.02 |
| SMA50 | $54.14 |
| SMA200 | $37.59 |
| RSI | 80.53 |
| ATR | 5.0371 |
| Shares Float | 62.65M |
| Short Float | 13.91% |
| Short Ratio | 6.05 |
| Volatility | 0.59 |
| Rel Volume | 0.80 |
Performance History
| Week | +11.07% |
| Month | +23.88% |
| Quarter | +114.60% |
| 6 Months | +118.77% |
| YTD | +140.57% |
| Year | +469.68% |
| 3 Years | +775.32% |
| 5 Years | +2750.57% |
| 10 Years | +580.54% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $75.54 | 2,086,800 |
| 2026-06-23 | $74.04 | 1,705,700 |
| 2026-06-22 | $75.49 | 2,908,600 |
| 2026-06-18 | $71.07 | 12,433,700 |
| 2026-06-17 | $68.65 | 1,710,400 |
| 2026-06-16 | $68.01 | 2,323,600 |
| 2026-06-15 | $71.80 | 2,103,800 |
| 2026-06-12 | $71.23 | 1,693,900 |
| 2026-06-11 | $71.63 | 3,322,000 |
| 2026-06-10 | $65.25 | 2,330,000 |
| 2026-06-09 | $64.01 | 1,624,100 |
| 2026-06-08 | $63.90 | 3,159,500 |
| 2026-06-05 | $61.85 | 1,704,200 |
| 2026-06-04 | $62.54 | 4,398,600 |
| 2026-06-03 | $55.69 | 1,393,200 |
| 2026-06-02 | $55.11 | 2,293,900 |
| 2026-06-01 | $58.75 | 1,339,100 |
| 2026-05-29 | $61.86 | 1,331,000 |
| 2026-05-28 | $62.03 | 840,100 |
| 2026-05-27 | $62.03 | 1,350,300 |
| 2026-05-26 | $60.10 | 1,286,900 |
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
đ° Latest News
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Zacks âĸ 2026-06-24T14:13:00Z
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Zacks âĸ 2026-06-24T14:05:00Z
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Zacks âĸ 2026-06-23T15:24:00Z
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Zacks âĸ 2026-06-23T14:59:00Z
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Zacks âĸ 2026-06-23T14:52:00Z
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Zacks âĸ 2026-06-23T14:46:00Z
3 Best Low-Beta Stocks to Buy Right Away: LQDA, FLXS & AGX
Zacks âĸ 2026-06-23T12:01:00ZBull of the Day: Liquidia Corporation (LQDA)
Zacks âĸ 2026-06-23T08:30:00Z
Liquidia and Goodyear have been highlighted as Zacks Bull and Bear of the Day
Zacks âĸ 2026-06-23T07:47:00Z
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
Zacks âĸ 2026-06-22T14:29:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $13,242,000 | $5,879,000 | $2,888,000 | $2,859,000 |
| Cost Of Revenue | $13,242,000 | $5,879,000 | $2,888,000 | $2,859,000 |
| Total Revenue | $158,320,000 | $13,996,000 | $17,488,000 | $15,935,000 |
| Operating Revenue | $158,320,000 | $13,996,000 | $17,488,000 | $15,935,000 |
| Expenses | ||||
| Interest Expense | $24,172,000 | $14,651,000 | $6,273,000 | $2,338,000 |
| Total Expenses | $209,696,000 | $135,290,000 | $90,872,000 | $54,705,000 |
| Net Non Operating Interest Income Expense | $-17,548,000 | $-6,997,000 | $-2,807,000 | $-1,248,000 |
| Interest Expense Non Operating | $24,172,000 | $14,651,000 | $6,273,000 | $2,338,000 |
| Operating Expense | $196,454,000 | $129,411,000 | $87,984,000 | $51,846,000 |
| General And Administrative Expense | $157,178,000 | $81,569,000 | $44,742,000 | $32,411,000 |
| Other Income Expense | - | $-4,268,000 | $-2,311,000 | $-997,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Net Interest Income | $-17,548,000 | $-6,997,000 | $-2,807,000 | $-1,248,000 |
| Interest Income | $6,624,000 | $7,654,000 | $3,466,000 | $1,090,000 |
| Normalized Income | $-68,924,000 | $-128,291,000 | $-76,191,000 | $-40,018,000 |
| Net Income From Continuing And Discontinued Operation | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Total Operating Income As Reported | $-51,376,000 | $-121,294,000 | $-73,384,000 | $-38,770,000 |
| Net Income Common Stockholders | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Net Income | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Net Income Including Noncontrolling Interests | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Net Income Continuous Operations | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Pretax Income | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Special Income Charges | $0 | $0 | $-2,311,000 | $-997,000 |
| Interest Income Non Operating | $6,624,000 | $7,654,000 | $3,466,000 | $1,090,000 |
| Operating Income | $-51,376,000 | $-121,294,000 | $-73,384,000 | $-38,770,000 |
| Gross Profit | $145,078,000 | $8,117,000 | $14,600,000 | $13,076,000 |
| Per Share | ||||
| Diluted EPS | $-0.80 | $-1.66 | $-1.21 | $-0.67 |
| Basic EPS | $-0.80 | $-1.66 | $-1.21 | $-0.67 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-43,224,000 | $-111,443,000 | $-67,740,000 | $-34,033,000 |
| Total Unusual Items | $0 | $0 | $-2,311,000 | $-997,000 |
| Total Unusual Items Excluding Goodwill | $0 | $0 | $-2,311,000 | $-997,000 |
| Reconciled Depreciation | $1,528,000 | $2,197,000 | $2,178,000 | $3,647,000 |
| EBITDA (Bullshit earnings) | $-43,224,000 | $-111,443,000 | $-70,051,000 | $-35,030,000 |
| EBIT | $-44,752,000 | $-113,640,000 | $-72,229,000 | $-38,677,000 |
| Diluted Average Shares | $86,059,101 | $78,707,503 | $64,993,476 | $60,958,862 |
| Basic Average Shares | $86,059,101 | $78,707,503 | $64,993,476 | $60,958,862 |
| Diluted NI Availto Com Stockholders | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Research And Development | $39,276,000 | $47,842,000 | $43,242,000 | $19,435,000 |
| Selling General And Administration | $157,178,000 | $81,569,000 | $44,742,000 | $32,411,000 |
| Other Gand A | $157,178,000 | $81,569,000 | $44,742,000 | $32,411,000 |
| Other Special Charges | - | $4,268,000 | $2,311,000 | $997,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $37,893,000 | $72,319,000 | $39,960,000 | $82,793,000 |
| Total Assets | $327,934,000 | $230,313,000 | $118,332,000 | $129,198,000 |
| Total Non Current Assets | $54,533,000 | $45,208,000 | $28,433,000 | $29,387,000 |
| Other Non Current Assets | $25,067,000 | $18,378,000 | $6,994,000 | $6,902,000 |
| Non Current Deferred Assets | $6,818,000 | $7,286,000 | $7,922,000 | $8,604,000 |
| Goodwill And Other Intangible Assets | $6,855,000 | $7,059,000 | $7,333,000 | $7,629,000 |
| Other Intangible Assets | $2,952,000 | $3,156,000 | $3,430,000 | $3,726,000 |
| Current Assets | $273,401,000 | $185,105,000 | $89,899,000 | $99,811,000 |
| Other Current Assets | $4,826,000 | $5,666,000 | $2,159,000 | $1,511,000 |
| Inventory | $23,802,000 | $241,000 | $0 | - |
| Receivables | $54,093,000 | $2,719,000 | $4,061,000 | $5,017,000 |
| Accounts Receivable | $54,093,000 | $2,719,000 | $4,061,000 | $5,017,000 |
| Cash Cash Equivalents And Short Term Investments | $190,680,000 | $176,479,000 | $83,679,000 | $93,283,000 |
| Cash And Cash Equivalents | $190,680,000 | $176,479,000 | $83,679,000 | $93,283,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $661,000 | - | - | - |
| Total Debt | $197,927,000 | $120,287,000 | $49,536,000 | $24,463,000 |
| Long Term Debt And Capital Lease Obligation | $139,034,000 | $101,854,000 | $45,782,000 | $23,382,000 |
| Long Term Debt | $132,935,000 | $95,268,000 | $43,418,000 | $19,879,000 |
| Current Debt And Capital Lease Obligation | $58,893,000 | $18,433,000 | $3,754,000 | $1,081,000 |
| Current Debt | $58,406,000 | $18,016,000 | $2,615,000 | - |
| Other Current Borrowings | $58,406,000 | $18,016,000 | $2,615,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $283,186,000 | $150,935,000 | $71,039,000 | $38,776,000 |
| Total Non Current Liabilities Net Minority Interest | $147,418,000 | $109,154,000 | $52,489,000 | $29,976,000 |
| Tradeand Other Payables Non Current | $8,384,000 | $7,300,000 | $6,707,000 | $6,594,000 |
| Current Liabilities | $135,768,000 | $41,781,000 | $18,550,000 | $8,800,000 |
| Payables And Accrued Expenses | $56,556,000 | $13,097,000 | $6,252,000 | $4,857,000 |
| Payables | $3,678,000 | $4,689,000 | $1,396,000 | $2,197,000 |
| Accounts Payable | $3,678,000 | $4,689,000 | $1,396,000 | $2,197,000 |
| Other Payable | - | - | $2,615,000 | - |
| Equity | ||||
| Common Stock Equity | $44,748,000 | $79,378,000 | $47,293,000 | $90,422,000 |
| Total Equity Gross Minority Interest | $44,748,000 | $79,378,000 | $47,293,000 | $90,422,000 |
| Stockholders Equity | $44,748,000 | $79,378,000 | $47,293,000 | $90,422,000 |
| Retained Earnings | $-626,313,000 | $-557,389,000 | $-429,098,000 | $-350,596,000 |
| Other | ||||
| Ordinary Shares Number | $87,204,137 | $84,683,063 | $68,629,575 | $64,517,912 |
| Share Issued | $87,204,137 | $84,683,063 | $68,629,575 | $64,517,912 |
| Tangible Book Value | $37,893,000 | $72,319,000 | $39,960,000 | $82,793,000 |
| Invested Capital | $236,089,000 | $192,662,000 | $93,326,000 | $110,301,000 |
| Working Capital | $137,633,000 | $143,324,000 | $71,349,000 | $91,011,000 |
| Capital Lease Obligations | $6,586,000 | $7,003,000 | $3,503,000 | $4,584,000 |
| Total Capitalization | $177,683,000 | $174,646,000 | $90,711,000 | $110,301,000 |
| Additional Paid In Capital | $670,974,000 | $636,682,000 | $476,322,000 | $440,954,000 |
| Capital Stock | $87,000 | $85,000 | $69,000 | $64,000 |
| Common Stock | $87,000 | $85,000 | $69,000 | $64,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $6,099,000 | $6,586,000 | $2,364,000 | $3,503,000 |
| Current Capital Lease Obligation | $487,000 | $417,000 | $1,139,000 | $1,081,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $20,319,000 | $10,251,000 | $8,544,000 | $2,862,000 |
| Current Accrued Expenses | $52,878,000 | $8,408,000 | $4,856,000 | $2,660,000 |
| Goodwill | $3,903,000 | $3,903,000 | $3,903,000 | $3,903,000 |
| Net PPE | $15,793,000 | $12,485,000 | $6,184,000 | $6,252,000 |
| Accumulated Depreciation | $-13,968,000 | $-15,809,000 | $-15,314,000 | $-14,114,000 |
| Gross PPE | $29,761,000 | $28,294,000 | $21,498,000 | $20,366,000 |
| Leases | $13,028,000 | $12,959,000 | $11,409,000 | $11,409,000 |
| Construction In Progress | $5,091,000 | $3,001,000 | $804,000 | $155,000 |
| Other Properties | $9,180,000 | $11,105,000 | $8,538,000 | $8,358,000 |
| Machinery Furniture Equipment | $2,462,000 | $1,229,000 | $747,000 | $444,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-42,022,000 | $-101,871,000 | $-52,854,000 | $-29,180,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-35,686,000 | $-93,422,000 | $-41,564,000 | $-28,588,000 |
| Cash Flow From Continuing Operating Activities | $-35,686,000 | $-93,422,000 | $-41,564,000 | $-28,588,000 |
| Operating Gains Losses | $11,000 | $46,000 | $2,309,000 | $1,001,000 |
| Investing Activities | ||||
| Capital Expenditure | $-6,336,000 | $-8,449,000 | $-11,290,000 | $-592,000 |
| Investing Cash Flow | $-6,336,000 | $-8,441,000 | $-11,288,000 | $-587,000 |
| Cash Flow From Continuing Investing Activities | $-6,336,000 | $-8,441,000 | $-11,288,000 | $-587,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $138,551,000 | $24,238,000 | $54,461,000 |
| Financing Cash Flow | $59,727,000 | $194,663,000 | $43,248,000 | $64,964,000 |
| Cash Flow From Continuing Financing Activities | $59,727,000 | $194,663,000 | $43,248,000 | $64,964,000 |
| Net Other Financing Charges | $1,084,000 | $593,000 | $113,000 | $451,000 |
| Net Common Stock Issuance | $0 | $138,551,000 | $24,238,000 | $54,461,000 |
| Common Stock Issuance | $0 | $138,551,000 | $24,238,000 | $54,461,000 |
| Other | ||||
| Repayment Of Debt | $-21,154,000 | $-4,960,000 | $-24,025,000 | $-10,811,000 |
| Issuance Of Debt | $74,975,000 | $57,460,000 | $41,744,000 | $19,767,000 |
| Interest Paid Supplemental Data | $0 | $0 | $360,000 | $1,626,000 |
| End Cash Position | $194,184,000 | $176,479,000 | $83,679,000 | $93,283,000 |
| Beginning Cash Position | $176,479,000 | $83,679,000 | $93,283,000 | $57,494,000 |
| Changes In Cash | $17,705,000 | $92,800,000 | $-9,604,000 | $35,789,000 |
| Proceeds From Stock Option Exercised | $4,822,000 | $3,019,000 | $1,178,000 | $1,096,000 |
| Net Issuance Payments Of Debt | $53,821,000 | $52,500,000 | $17,719,000 | $8,956,000 |
| Net Long Term Debt Issuance | $53,821,000 | $52,500,000 | $17,719,000 | $8,956,000 |
| Long Term Debt Payments | $-21,154,000 | $-4,960,000 | $-24,025,000 | $-10,811,000 |
| Long Term Debt Issuance | $74,975,000 | $57,460,000 | $41,744,000 | $19,767,000 |
| Net Intangibles Purchase And Sale | $-2,000,000 | $-3,500,000 | $-10,000,000 | $0 |
| Purchase Of Intangibles | $-2,000,000 | $-3,500,000 | $-10,000,000 | $0 |
| Net PPE Purchase And Sale | $-4,336,000 | $-4,941,000 | $-1,288,000 | $-587,000 |
| Sale Of PPE | $0 | $8,000 | $2,000 | $5,000 |
| Purchase Of PPE | $-4,336,000 | $-4,949,000 | $-1,290,000 | $-592,000 |
| Change In Working Capital | $-24,183,000 | $-4,792,000 | $5,872,000 | $-2,158,000 |
| Change In Other Current Liabilities | $-353,000 | $-970,000 | $-900,000 | $-775,000 |
| Change In Other Current Assets | $-2,253,000 | $-10,631,000 | $20,000 | $4,000 |
| Change In Payables And Accrued Expense | $51,945,000 | $7,589,000 | $6,594,000 | $1,359,000 |
| Change In Accrued Expense | $54,538,000 | $5,259,000 | $7,746,000 | $545,000 |
| Change In Payable | $-2,593,000 | $2,330,000 | $-1,152,000 | $814,000 |
| Change In Account Payable | $-2,593,000 | $2,330,000 | $-1,152,000 | $814,000 |
| Change In Prepaid Assets | $840,000 | $-1,881,000 | $-798,000 | $-719,000 |
| Change In Inventory | $-22,988,000 | $-241,000 | $0 | - |
| Change In Receivables | $-51,374,000 | $1,342,000 | $956,000 | $-2,027,000 |
| Changes In Account Receivables | $-51,374,000 | $1,342,000 | $956,000 | $-2,027,000 |
| Other Non Cash Items | $26,410,000 | $18,612,000 | $16,490,000 | $639,000 |
| Stock Based Compensation | $29,472,000 | $18,806,000 | $10,089,000 | $9,298,000 |
| Depreciation Amortization Depletion | $1,528,000 | $2,197,000 | $2,178,000 | $3,647,000 |
| Depreciation And Amortization | $1,528,000 | $2,197,000 | $2,178,000 | $3,647,000 |
| Gain Loss On Sale Of PPE | $11,000 | $46,000 | $-2,000 | $4,000 |
| Net Income From Continuing Operations | $-68,924,000 | $-128,291,000 | $-78,502,000 | $-41,015,000 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-24